NEW YORK (GenomeWeb) – KromaTid today announced it has selected Tebu-bio as its European distribution partner.
Tebu-bio will distribute Fort Collins, Colo.-based KromaTid's genome imaging assays, which can determine DNA sequence, location, and orientation in a single test. KromaTiD's assays can detect genetic rearrangements, such as chromosomal inversions and translocations, that are missed by other diagnostic tools, the firm said in a statement.
Tebu-bio is based in Le Perray, France and has offices in Belgium, Germany, Italy, the Netherlands, Denmark, Finland, Norway, Sweden, Portugal, Spain, and the UK.
"KromaTid's ability to quickly design and produce custom assays for nearly any chromosomal rearrangement is an innovation that will generate a great deal of interest from our European pharmaceutical customers," Mark Livingstone, head of molecular biology at Tebu-bio, said in a statement.
In January 2014, Tebu-bio signed an agreement with EpiCypher to distribute the firm's epigenetics and chromatic biology research products in Europe.
Financial and other terms of today's agreement were not disclosed.